KRAS and cancer: Our design strategy and discovery pipeline may be applicable to many oncogenic mutations for which covalent ligands can be developed (Visscher et al., 2016), particularly the recurrent somatic mutations to cysteine residues such as KRAS G12C, TP53 Y220C, GNAS R201C, and IDH1 R132C which together are present in roughly 5% of all cancers.